Last reviewed · How we verify
Dopamine administration
Dopamine administration directly replaces or supplements dopamine, a neurotransmitter that activates dopamine receptors in the central and peripheral nervous system.
Dopamine administration directly replaces or supplements dopamine, a neurotransmitter that activates dopamine receptors in the central and peripheral nervous system. Used for Hypotension and shock (cardiogenic, septic, hypovolemic), Heart failure with reduced cardiac output, Acute kidney injury with oliguria.
At a glance
| Generic name | Dopamine administration |
|---|---|
| Sponsor | University of California, Davis |
| Drug class | Catecholamine; sympathomimetic amine |
| Target | Dopamine receptors (D1, D2, D3, D4, D5); β-adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular; Critical Care |
| Phase | FDA-approved |
Mechanism of action
Dopamine is a catecholamine neurotransmitter that binds to dopamine receptors (D1-D5) to modulate motor control, motivation, reward, and cardiovascular function. When administered exogenously, dopamine crosses the blood-brain barrier minimally due to its polar structure, making it primarily useful for peripheral effects on heart rate, blood pressure, and renal perfusion via D1 and β-adrenergic receptor activation.
Approved indications
- Hypotension and shock (cardiogenic, septic, hypovolemic)
- Heart failure with reduced cardiac output
- Acute kidney injury with oliguria
Common side effects
- Tachycardia
- Hypertension
- Arrhythmias
- Vasoconstriction
- Nausea
- Headache
Key clinical trials
- Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons (PHASE1)
- Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol (PHASE3)
- Dopamine Modulation of Motivation and Motor Function in Major Depression & Inflammation (NA)
- ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors (PHASE1)
- Characterizing Dopamine Receptor Binding in Treatment Resistant Depression
- Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease. (PHASE2)
- Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease (PHASE3)
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |